Catalyst Pharma ' s Neuromuscular Drug Succeeds in Study Catalyst Pharma ' s Neuromuscular Drug Succeeds in Study

Catalyst Pharmaceuticals Inc said on Wednesday its experimental drug to treat patients with a severe form of myasthenia gravis (MG), a rare neuromuscular disease, met the main goals of a study.Reuters Health Information
Source: Medscape Allergy Headlines - Category: Allergy & Immunology Tags: Neurology & Neurosurgery News Source Type: news